US Edition
News from endpoints.news
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top endpoints.news News
Vaccines · United StatesHealth and Human Services Secretary Robert F. Kennedy Jr.'s influential vaccine advisory panel on Thursday delayed a vote for a second time on whether to change the timing of the first dose of the hepatitis B vaccine for newborns.
See the Story
RFK Jr.’s vaccine panel defers vote on hepatitis B shot for babies until Friday
55% Center coverage: 47 sources
Startups · ShanghaiSHANGHAI, Dec. 4, 2025 /PRNewswire/ -- OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, emerged from stealth and announced today the successful completion of a $100 million Series A financing closed in June 2025.…See the Story
OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies
65% Center coverage: 29 sources
FDA · United StatesOn Thursday, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb & Co.’s (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL). Breyanzi is administered as a one-time infusion. Breyanzi is now the only CAR T cell therapy approved by the FDA for five cancer types, the most of a…See the Story
What's Going On With Bristol-Myers Squibb Stock Friday? - Bristol-Myers Squibb (NYSE:BMY)
75% Center coverage: 4 sources
